Rebecca Zhang-Roper

Hepatic Safety of Maraviroc in Patients with HIV-1 and Hepatitis C and/or B Virus: 144-Week Results from a Randomized, Placebo-Controlled Trial

D. Asmuth, G. Fätkenheuer, G. Pialoux, 2017, Antiviral therapy.

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

C. Giaquinto, L. Mcfadyen, C. Craig, 2017, The Pediatric infectious disease journal.